Statement 2 February 2023

Prevention and control of non-communicable diseases and mental health (EB152)


On 2 February 2023, IFPMA attended the 152nd session of the Executive Board at the World Health Organization in Geneva. IFPMA delivered a statement for the agenda item related to the prevention and control of non-communicable diseases and mental health.

We support the draft decision on NCDs and mental health and the update of Appendix 3 to expand the scope of highly recommended interventions for NCD prevention and control. Under-resourced health systems and inadequate investment that is sufficient and sustainable in NCD prevention and control hamper the long-term ability to proactively address health crises. We welcome the WHO’s continued work on NCDs and trust that NCDs will be a cornerstone of discussions at the 2nd High Level Meeting on UHC this year, alongside other treatable and preventable communicable diseases.

The industry remains a willing and critical partner in addressing gaps in NCD response. We maintain our commitment to tackling NCDs and will continue working with others to build access solutions and contribute toward stronger health systems, with the aim of improving the lives of people living with NCDs.


The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit

Learn more

Media Contact

Elliot Dunster